Renia Coghlan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Renia Coghlan has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Allan Batte
Programme for Accessible Health Communication and Education-PACE, Kampala, Uganda
1 shared publication - Ambrose Talisuna
World Wide Antimalarial Resistance Network (WWARN), Malaria Public Health Department, University of Oxford/KEMRI/Wellcome Trust Research Programme, PO Box 43640, 00100, Nairobi, Kenya
1 shared publication - Andrew Balyeku
Medicines for Malaria Venture-MMV, PO Box 1826 20, rte de Pré-Bois, Geneva 15, 1215, Switzerland
1 shared publication - Angela Bonabana
Uganda National Drug Authority-NDA, Kampala, Uganda
1 shared publication - Bram Piot
Medicines for Malaria Venture-MMV, PO Box 1826 20, rte de Pré-Bois, Geneva 15, 1215, Switzerland
1 shared publication - David Nahamya
Uganda National Drug Authority-NDA, Kampala, Uganda
1 shared publication
Latest Publications
- Open Access
- 29 October 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 356
Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.
- 29 October 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 356
Open AccessClosing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.
- Open Access
- 22 September 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 279
Knowledge and malaria treatment practices using artemisinin combination therapy (ACT) in Malawi: survey of health professionals
Malaria still remains a life-threatening disease worldwide causing between 190 and 311 million cases of malaria in 2008. Due to increased resistance to sulphadoxine-pyrimethamine (SP), the Ministry of Health in Malawi, as in many sub-Saharan African countries, changed the malaria treatment policy to use artemisinin-based combination therapy (ACT). In order to optimize the correct use of this drug, and protect against the development of the parasite's resistance, it is important to assess the knowledge and practices of medical practitioners on the use of ACT and its impact on adherence to new treatment policy guidelines.
- 22 September 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 279
Open AccessKnowledge and malaria treatment practices using artemisinin combination therapy (ACT) in Malawi: survey of health professionals
Malaria still remains a life-threatening disease worldwide causing between 190 and 311 million cases of malaria in 2008. Due to increased resistance to sulphadoxine-pyrimethamine (SP), the Ministry of Health in Malawi, as in many sub-Saharan African countries, changed the malaria treatment policy to use artemisinin-based combination therapy (ACT). In order to optimize the correct use of this drug, and protect against the development of the parasite's resistance, it is important to assess the knowledge and practices of medical practitioners on the use of ACT and its impact on adherence to new treatment policy guidelines.